Delivering antibodies directly to the brain using imaging technology
Image-guided, intra-arterial delivery of antibodies to the central nervous system
['FUNDING_R01'] · UNIVERSITY OF MARYLAND BALTIMORE · NIH-11049201
This study is exploring a new way to deliver helpful antibodies directly to the brain using real-time MRI, which could make treatments for brain tumors and other neurological issues more effective and safer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MARYLAND BALTIMORE (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-11049201 on ClinicalTrials.gov |
What this research studies
This research investigates a novel method for delivering therapeutic antibodies directly to the central nervous system (CNS) using real-time MRI guidance. By utilizing an intra-arterial delivery approach, the study aims to overcome the challenges posed by the blood-brain barrier, which typically limits the effectiveness of larger therapeutic molecules like antibodies. The researchers have developed a technique that allows for precise targeting and imaging of these antibodies, potentially improving treatment outcomes for various CNS diseases. This method could enhance the specificity and safety of treatments for conditions such as brain tumors and neurological disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with neurological, oncological, or psychiatric conditions affecting the central nervous system.
Not a fit: Patients with conditions not related to the central nervous system or those who do not require antibody-based therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment options for patients with central nervous system diseases by enabling more effective delivery of therapeutic antibodies.
How similar studies have performed: While the approach of intra-arterial delivery has been attempted before, the combination of real-time MRI guidance and antibody radiolabeling is a novel strategy that has shown promising early results.
Where this research is happening
BALTIMORE, UNITED STATES
- UNIVERSITY OF MARYLAND BALTIMORE — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JANOWSKI, MIROSLAW — UNIVERSITY OF MARYLAND BALTIMORE
- Study coordinator: JANOWSKI, MIROSLAW
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.